Older patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) who were not good candidates for the standard treatment of intensive chemotherapy had a median overall survival (OS) of 6.5 years on an alternate regimen of dasatinib and blinatumomab.
Long-term results show combination treatment that skips chemotherapy is effective for older patients with Ph+ ALL medicalxpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medicalxpress.com Daily Mail and Mail on Sunday newspapers.
Combo Treatment Sans Chemotherapy Effective for Ph+ ALL Elderly miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.
The study findings add new insights, but also raise new questions, about the best treatment approach for Philadelphia chromosome-positive acute lymphoblastic leukemia.
The combination of dasatinib, blinatumomab, and prednisone can be effective in treating older patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) who are not good candidates for intensive chemotherapy treatment.